JiuZhou Pharma’s Near-Term Carbon Reduction Targets Validated by the SBTi
Release time:
2025-11-29
On November 11, 2025, JiuZhou Pharma’s near-term greenhouse gas (GHG) emission reduction targets successfully passed the rigorous review of the Science Based Targets initiative (SBTi) and have been officially validated. As a globally recognized authority on science-based carbon target assessment, SBTi’s validation signifies that JiuZhou Pharma’s decarbonization pathway not only meets international scientific standards but is also fully aligned with the core goal of the Paris Agreement—to limit global temperature rise to within 1.5°C.
Near-Term Targets
JiuZhou Pharma commits to reducing its absolute Scope 1 and Scope 2 GHG emissions by 42.0% by 2030, using 2024 as the base year. In addition, the company commits to reducing absolute Scope 3 emissions—specifically from purchased goods and services, and fuel- and energy-related activities—by 25.0% over the same period.
These targets cover the company’s core operations and critical areas across the supply chain, reflecting JiuZhou Pharma’s determination to drive decarbonization across the entire value chain.
To achieve these goals, the company is actively implementing multi-dimensional measures including process optimization, equipment upgrades, green electricity procurement, and the installation of self-built photovoltaic systems. These efforts continuously enhance energy efficiency and increase the share of renewable energy. At the same time, JiuZhou Pharma is collaborating with key suppliers to jointly build a low-carbon supply chain, sharing best practices and promoting coordinated decarbonization across the industry.
JiuZhou Pharma will take SBTi validation as a new starting point to further strengthen green technology innovation and ESG practices. By working closely with global partners, suppliers, and stakeholders, the company will continue to advance in environmental responsibility, social responsibility, and corporate governance—striking a balance between industrial growth and carbon reduction. Through green pharmaceutical technologies that protect human health and sustainable actions that support global climate efforts, JiuZhou Pharma aims to achieve a win-win outcome for business growth, environmental protection, and social well-being, contributing “JiuZhou strength” to the development of a healthy and low-carbon global pharmaceutical ecosystem.
Other News
Understanding Small Molecule Drug Manufacturing: Mastering the Future of Drug Production
On November 11, 2025, JiuZhou Pharma’s near-term greenhouse gas (GHG) emission reduction targets successfully passed the rigorous review of the Science Based Targets initiative (SBTi) and have been officially validated. As a globally recognized authority on science-based carbon target assessment, SBTi’s validation signifies that JiuZhou Pharma’s decarbonization pathway not only meets international scientific standards but is also fully aligned with the core goal of the Paris Agreement—to limit global temperature rise to within 1.5°C.
Near-Term Targets
JiuZhou Pharma commits to reducing its absolute Scope 1 and Scope 2 GHG emissions by 42.0% by 2030, using 2024 as the base year. In addition, the company commits to reducing absolute Scope 3 emissions—specifically from purchased goods and services, and fuel- and energy-related activities—by 25.0% over the same period.
These targets cover the company’s core operations and critical areas across the supply chain, reflecting JiuZhou Pharma’s determination to drive decarbonization across the entire value chain.
To achieve these goals, the company is actively implementing multi-dimensional measures including process optimization, equipment upgrades, green electricity procurement, and the installation of self-built photovoltaic systems. These efforts continuously enhance energy efficiency and increase the share of renewable energy. At the same time, JiuZhou Pharma is collaborating with key suppliers to jointly build a low-carbon supply chain, sharing best practices and promoting coordinated decarbonization across the industry.
JiuZhou Pharma will take SBTi validation as a new starting point to further strengthen green technology innovation and ESG practices. By working closely with global partners, suppliers, and stakeholders, the company will continue to advance in environmental responsibility, social responsibility, and corporate governance—striking a balance between industrial growth and carbon reduction. Through green pharmaceutical technologies that protect human health and sustainable actions that support global climate efforts, JiuZhou Pharma aims to achieve a win-win outcome for business growth, environmental protection, and social well-being, contributing “JiuZhou strength” to the development of a healthy and low-carbon global pharmaceutical ecosystem.
2025-12-03
JiuZhou Pharma’s Near-Term Carbon Reduction Targets Validated by the SBTi
On November 11, 2025, JiuZhou Pharma’s near-term greenhouse gas (GHG) emission reduction targets successfully passed the rigorous review of the Science Based Targets initiative (SBTi) and have been officially validated. As a globally recognized authority on science-based carbon target assessment, SBTi’s validation signifies that JiuZhou Pharma’s decarbonization pathway not only meets international scientific standards but is also fully aligned with the core goal of the Paris Agreement—to limit global temperature rise to within 1.5°C.
Near-Term Targets
JiuZhou Pharma commits to reducing its absolute Scope 1 and Scope 2 GHG emissions by 42.0% by 2030, using 2024 as the base year. In addition, the company commits to reducing absolute Scope 3 emissions—specifically from purchased goods and services, and fuel- and energy-related activities—by 25.0% over the same period.
These targets cover the company’s core operations and critical areas across the supply chain, reflecting JiuZhou Pharma’s determination to drive decarbonization across the entire value chain.
To achieve these goals, the company is actively implementing multi-dimensional measures including process optimization, equipment upgrades, green electricity procurement, and the installation of self-built photovoltaic systems. These efforts continuously enhance energy efficiency and increase the share of renewable energy. At the same time, JiuZhou Pharma is collaborating with key suppliers to jointly build a low-carbon supply chain, sharing best practices and promoting coordinated decarbonization across the industry.
JiuZhou Pharma will take SBTi validation as a new starting point to further strengthen green technology innovation and ESG practices. By working closely with global partners, suppliers, and stakeholders, the company will continue to advance in environmental responsibility, social responsibility, and corporate governance—striking a balance between industrial growth and carbon reduction. Through green pharmaceutical technologies that protect human health and sustainable actions that support global climate efforts, JiuZhou Pharma aims to achieve a win-win outcome for business growth, environmental protection, and social well-being, contributing “JiuZhou strength” to the development of a healthy and low-carbon global pharmaceutical ecosystem.
2025-11-29
Why Choose a CDMO to Enhance Small Molecule Drug Production
On November 11, 2025, JiuZhou Pharma’s near-term greenhouse gas (GHG) emission reduction targets successfully passed the rigorous review of the Science Based Targets initiative (SBTi) and have been officially validated. As a globally recognized authority on science-based carbon target assessment, SBTi’s validation signifies that JiuZhou Pharma’s decarbonization pathway not only meets international scientific standards but is also fully aligned with the core goal of the Paris Agreement—to limit global temperature rise to within 1.5°C.
Near-Term Targets
JiuZhou Pharma commits to reducing its absolute Scope 1 and Scope 2 GHG emissions by 42.0% by 2030, using 2024 as the base year. In addition, the company commits to reducing absolute Scope 3 emissions—specifically from purchased goods and services, and fuel- and energy-related activities—by 25.0% over the same period.
These targets cover the company’s core operations and critical areas across the supply chain, reflecting JiuZhou Pharma’s determination to drive decarbonization across the entire value chain.
To achieve these goals, the company is actively implementing multi-dimensional measures including process optimization, equipment upgrades, green electricity procurement, and the installation of self-built photovoltaic systems. These efforts continuously enhance energy efficiency and increase the share of renewable energy. At the same time, JiuZhou Pharma is collaborating with key suppliers to jointly build a low-carbon supply chain, sharing best practices and promoting coordinated decarbonization across the industry.
JiuZhou Pharma will take SBTi validation as a new starting point to further strengthen green technology innovation and ESG practices. By working closely with global partners, suppliers, and stakeholders, the company will continue to advance in environmental responsibility, social responsibility, and corporate governance—striking a balance between industrial growth and carbon reduction. Through green pharmaceutical technologies that protect human health and sustainable actions that support global climate efforts, JiuZhou Pharma aims to achieve a win-win outcome for business growth, environmental protection, and social well-being, contributing “JiuZhou strength” to the development of a healthy and low-carbon global pharmaceutical ecosystem.
2025-11-26
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039
E-mail: bd@jiuzhoupharma.com
